Physician profile
Joel Lopez-Figueroa
NPI 1811271463
$162,723.82
in general payments reported to CMS, 2019-2025
60 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,681 · 2020: $6,283 · 2021: $8,797 · 2022: $35K · 2023: $41K · 2024: $35K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Food and Beverage: $15K · Consulting Fee: $14K · Honoraria: $10K · Travel and Lodging: $1,767 · Education: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,869.60 |
| Food and Beverage | $14,597.57 |
| Consulting Fee | $14,030.00 |
| Honoraria | $10,140.00 |
| Travel and Lodging | $1,766.86 |
| Education | $604.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38,777.18 | 2019-2025 | Kyprolis, Kyprolis, Xgeva |
| Takeda Pharmaceuticals U.S.A., INC. | $18,385.21 | 2019-2025 | Advate |
| Lilly USA, LLC | $16,440.99 | 2024-2025 | Jaypirca |
| Karyopharm Therapeutics INC. | $16,098.17 | 2022-2025 | Xpovio |
| Celgene Corporation | $14,025.73 | 2019-2024 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $13,310.96 | 2019-2025 | Reblozyl, Opdivo, Breyanzi |
| Genzyme Corporation | $8,277.93 | 2019-2025 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $6,866.97 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Abbvie INC. | $6,407.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $5,483.94 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Rigel Pharmaceuticals, INC. | $2,913.25 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Astrazeneca Pharmaceuticals Lp | $1,781.81 | 2019-2025 | Tagrisso, Imfinzi, Lynparza |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2022 | |
| Eli Lilly and Company | $1,500.00 | 2025 | Jaypirca |
| Pbg Puerto Rico LLC | $1,310.28 | 2019-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,110.63 | 2019-2025 | |
| Astellas Pharma US INC | $894.58 | 2019-2025 | Xospata, Padcev |
| Tempus Ai, INC | $775.87 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $727.68 | 2020-2025 | Keytruda, Keytruda Qlex, Welireg |
| Genentech USA, INC. | $673.41 | 2019-2025 | Columvi, Polivy, Lunsumio |
| Eisai INC. | $537.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $514.77 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Pfizer INC. | $453.39 | 2019-2024 | |
| Incyte Corporation | $440.87 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Sanofi-Aventis U.S. LLC | $416.73 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $236.86 | 2022-2024 | Ultomiris |
| Puma Biotechnology, INC. | $200.47 | 2019-2024 | Nerlynx |
| Janssen Biotech, INC. | $198.95 | 2020-2022 | |
| Beigene USA, INC. | $187.09 | 2020-2024 | Brukinsa |
| Bayer Puerto Rico INC. | $170.61 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Adaptive Biotechnologies Corporation | $160.84 | 2022-2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $150.58 | 2024-2025 | Libtayo, Lynozyfic |
| Adc Therapeutics America, INC. | $143.42 | 2023-2025 | |
| Gilead Sciences, INC. | $125.00 | 2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $117.61 | 2020-2022 | |
| Sobi, INC | $117.51 | 2023-2025 | |
| Taiho Oncology, INC. | $100.92 | 2020-2023 | |
| Jazz Pharmaceuticals INC. | $100.43 | 2023-2025 | Defitelio |
| Morphosys, US INC. | $88.03 | 2021-2024 | Monjuvi |
| Genmab U.S., INC. | $87.94 | 2024-2025 | Epkinly |
| Kite Pharma, INC. | $87.01 | 2019 | |
| Exelixis INC. | $85.60 | 2019-2025 | Cabometyx |
| Partner Therapeutics, INC. | $67.92 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $65.58 | 2019-2020 | |
| Array Biopharma INC | $61.74 | 2021-2024 | Mektovi, Lorbrena, Braftovi |
| Clovis Oncology, INC. | $53.49 | 2019 | |
| Lantheus Medical Imaging, INC. | $51.96 | 2019-2020 | |
| Telix Pharmaceuticals | $47.90 | 2025 | Illuccix |
| Aveo Pharmaceuticals, INC. | $46.24 | 2024-2025 | |
| Caris Mpi, INC. | $43.22 | 2025 | Mi Cancer Seek |
| Springworks Therapeutics, INC. | $42.18 | 2024 | Ogsiveo |
| Verity Pharmaceuticals INC. | $40.05 | 2022-2023 | Akynzeo |
| Seagen INC. | $39.41 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $30.73 | 2019 | |
| Kyowa Kirin, INC. | $25.00 | 2023 | Poteligeo |
| Mirati Therapeutics, INC. | $24.53 | 2023 | Krazati |
| Global Blood Therapeutics, INC. | $24.00 | 2022 | |
| Syndax Pharmaceuticals, INC. | $23.87 | 2025 | |
| Tolmar, INC. | $18.29 | 2023 | |
| Pfizer Pharmaceuticals LLC | $18.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Lopez-Figueroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.